286 results on '"Till, Brian"'
Search Results
2. HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation
3. Institutional Experience With Robotic Lobectomy After Neoadjuvant Immunotherapy and Chemotherapy
4. Geographic Variation in the Utilization of Services Surrounding Lung Cancer Resection
5. Global Cardiac Surgical Volume and Gaps: Trends, Targets, and Way Forward
6. Individual- and neighborhood-level characteristics of lung cancer screening participants undergoing telemedicine shared decision making
7. Access to Guideline Concordant Care for Node-Positive Non-Small Cell Lung Cancer in the United States
8. The Safety of Robotic Pneumonectomy
9. Lung Cancer Myths and How Do I Address Them?
10. Mentorship: How to Spot a Good Mentor and Hold on Tight
11. Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
12. Impact and Durability of the Affordable Care Act Medicaid Expansion on Lung Cancer Treatment
13. Association Between Utilization of Services and Perioperative Outcomes for Lung Cancer Resection
14. Cessation of Routine Jejunostomy Tube Placement at Time of Minimally Invasive Ivor Lewis Esophagectomy and Impact on Body Mass Index
15. Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients
16. Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy
17. Intraoperative Versus Preoperative Diagnosis of Lung Cancer: Differences in Treatments and Patient Outcomes
18. Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
19. Is wedge a dirty word? Demographic and facility-level variables associated with high-quality wedge resection
20. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial
21. Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma
22. Robotic Minimally Invasive Esophagectomy
23. Impact of stereotactic body radiation therapy volume on surgical patient selection, short-term survival, and long-term survival in early-stage non–small cell lung cancer
24. Patients (pts) with R/R large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) nonconforming product (NCP) under the Expanded Access Protocol (EAP).
25. Early prediction of severe ICANS after standard-of-care CD19 CAR T-cell therapy using gradient-boosted classification trees.
26. Predictors of severe hematotoxicity after CAR T-cell therapy.
27. Characteristics of High-Volume Lung Segmentectomy Hospitals: A Propensity Score-Matched Analysis
28. Race is a Risk Factor for the Deferral of Resection and Radiation for Early-Stage Lung Cancer
29. Facility-level national trends in racial disparities of surgical therapy for early-stage lung cancer
30. The Creative Knife: Does Interference Dull the Edge of Creativity Effectiveness?
31. Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B‐Cell Lymphoma: Results from a Phase 1b Study
32. Role of fibrosarcoma-induced CD11b+ myeloid cells and tumor necrosis factor-α in B cell responses
33. Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up
34. Early Prediction of Severe Icans after CD19 CAR T-Cell Therapy Based on Serum Ferritin Levels
35. Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis
36. Safety and Efficacy of Fully-Human-Binder-Bearing CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma after Failure of Murine-Binder-Bearing CD19 CAR T-Cell Therapy
37. Post-CAR-T Checkpoint Inhibition Can Result in Durable Responses in a Minority of Patients with Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL): Results of a Phase 2 Study of Nivolumab after CAR-T Failure
38. Identification and Prediction of Severe Hematologic Toxicity after CAR T-Cell Therapy Using Machine Learning-Based Time-Series Clustering
39. Identification of Predictors of CRS and Neurotoxicity Duration after Axicabtagene Ciloleucel Therapy
40. Planned Interim Analysis of a Phase 2 Investigator-Initiated Trial of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel
41. Real-World Comparison of Lisocabtagene Maraleucel (Liso-Cel) and Axicabtagene Ciloleucel (Axi-Cel): Efficacy & Toxicity
42. T-Cell Large Granular Lymphocyte Population Involving Chimeric Antigen Receptor-Modified T (CAR T) Cells in Patients with Cytopenia after CD19-Targeted CAR T-Cell Therapy: Case Series
43. Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic
44. Upper Hemisternotomy Versus Full Sternotomy for Replacement of the Supracoronary Ascending Aorta and Aortic Valve
45. Lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma: feasibility, safety and efficacy in a real-world setting
46. Factors associated with long-term outcomes of CD19 chimeric antigen receptor T-cell therapy for relapsedrefractory chronic lymphocytic leukemia 6-year follow-up
47. Brief Report: Non-Malignant Resection Among Individuals with Screening-Detected vs. Incidental Lung Nodules
48. Global Cardiac Surgical Volume and Gaps: Trends, Targets, and Way Forward
49. Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel
50. 2711. Viral encephalitis after chimeric antigen receptor (CAR)-modified T-cell therapy: A Retrospective Cohort Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.